BLFE — Biolife Sciences Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.32m
- $0.61m
Annual income statement for Biolife Sciences, fiscal year end - November 30th, USD millions except per share, conversion factor applied.
2010 November 30th | 2011 November 30th | 2012 November 30th | 2020 November 30th | 2021 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.412 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | -0.985 | 0 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | -1.79 | 0.293 | 0.124 | 1.68 | 0.457 |
| Operating Profit | 1.79 | -0.293 | -0.124 | -1.27 | -0.457 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 1.72 | -0.293 | -0.202 | -1.27 | -0.457 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.72 | -0.293 | -0.202 | -1.27 | -0.457 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.72 | -0.293 | -0.202 | -1.27 | -0.457 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 1.72 | -0.293 | -0.202 | -1.27 | -0.457 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.26 | -0.63 | -0.937 | -0.025 | -0.008 |
| Dividends per Share |